Smith & Nephew (SNN)

• Market cap: $12.3B
• 1 day: 4.09%
• 5 days: 4.75%
• 1 month: -1.23%
• 3 months: 9.20%
• 6 months: -2.88%
• Year to date: 14.84%
• 1 year: 16.12%
• 5 years: -29.37%
• 10 years: -17.32%
• Sector: Healthcare
• Industry: Medical Devices

About: Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Employees: 17,349

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

276% more call options, than puts

Call options by funds: $933K | Put options by funds: $248K

100% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 2 (+1) [Q4]

29% more first-time investments, than exits

New positions opened: 40 | Existing positions closed: 31

21% more repeat investments, than reductions

Existing positions increased: 82 | Existing positions reduced: 68

2% more funds holding

Funds holding: 207 [Q3] → 212 (+5) [Q4]

0.34% more ownership

Funds ownership: 3.5% [Q3] → 3.85% (+0.34%) [Q4]

13% less capital invested

Capital invested by funds: $952M [Q3] → $827M (-$125M) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $27 4% downside
• Avg. target: $27 4% downside
• High target: $27 4% downside

2 analyst ratings

• positive: 0 0%
• neutral: 2 100%
• negative: 0 0%

Canaccord Genuity Caitlin Cronin 21% 1-year accuracy 3 / 14 met price target	4% downside $27	Hold Maintained	17 Mar 2025
Canaccord Genuity Kyle Rose 60% 1-year accuracy 3 / 5 met price target	4% downside $27	Hold Maintained	26 Feb 2025